Ivabradine Accord (Ivabradine Hydrochloride)

Ivabradine blocks the funny (If) current in the sino‑atrial node, which slows the spontaneous electrical activity that sets the heart’s rhythm. This selective inhibition reduces heart rate while preserving myocardial contractile force and systemic vascular resistance.

The specific dose of Ivabradine Accord is determined by the prescribing clinician based on the patient’s clinical status, heart‑rate targets, and tolerability. Dosage adjustments follow local prescribing guidelines and individual response.

Safety data for Ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Ivabradine and beta‑blockers lower heart rate, but Ivabradine does so by selectively inhibiting the If current without affecting beta‑adrenergic receptors, blood pressure, or contractility. This makes it useful when beta‑blockers are contraindicated or insufficient, though it does not replace the broader cardiovascular effects of beta‑blockers.

Ivabradine Accord should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in humid environments.

Ivabradine Accord is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. It is typically taken with or without food as directed by the prescriber.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe visual disturbances (phosphenes), and rare cases of hypotension. Patients should be monitored for these events, especially during dose titration or when combined with other heart‑rate‑lowering agents.

Ivabradine should not be used in patients with a resting heart rate below 50 bpm, those with acute decompensated heart failure, severe hepatic impairment, or known hypersensitivity to the drug. Caution is also advised in patients with sick sinus syndrome or atrial fibrillation.